<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="9" family="Arial,Italic" color="#000000"/>
	<fontspec id="font1" size="9" family="Arial" color="#000000"/>
	<fontspec id="font2" size="9" family="Arial,Bold" color="#000000"/>
	<fontspec id="font3" size="7" family="Arial,Italic" color="#000000"/>
	<fontspec id="font4" size="9" family="GillSans,BoldItalic" color="#000000"/>
	<fontspec id="font5" size="10" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font6" size="7" family="Giovanni-Book" color="#000000"/>
	<fontspec id="font7" size="10" family="Symbol" color="#000000"/>
	<fontspec id="font8" size="11" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font9" size="8" family="GillSans,Bold" color="#000000"/>
	<fontspec id="font10" size="8" family="GillSans" color="#000000"/>
<text top="41" left="55" width="73" height="10" font="font0" id="p1_t1" reading_order_no="0" segment_no="0" tag_type="title"><i>BMC Dermatology</i></text>
<text top="41" left="129" width="28" height="10" font="font1" id="p1_t2" reading_order_no="1" segment_no="0" tag_type="title"> 2006, </text>
<text top="41" left="156" width="5" height="10" font="font2" id="p1_t3" reading_order_no="2" segment_no="0" tag_type="title"><b>6</b></text>
<text top="41" left="161" width="7" height="10" font="font1" id="p1_t4" reading_order_no="3" segment_no="0" tag_type="title">:8</text>
<text top="41" left="373" width="181" height="10" font="font1" id="p1_t5" reading_order_no="4" segment_no="1" tag_type="text">http://www.biomedcentral.com/1471-5945/6/8</text>
<text top="756" left="508" width="46" height="10" font="font1" id="p1_t6" reading_order_no="114" segment_no="22" tag_type="text">Page 3 of 6</text>
<text top="769" left="432" width="122" height="8" font="font3" id="p1_t7" reading_order_no="115" segment_no="23" tag_type="text"><i>(page number not for citation purposes)</i></text>
<text top="87" left="55" width="98" height="9" font="font4" id="p1_t8" reading_order_no="5" segment_no="3" tag_type="title"><i><b>Prospective application</b></i></text>
<text top="98" left="55" width="241" height="9" font="font5" id="p1_t9" reading_order_no="6" segment_no="4" tag_type="text">SPC was applied prospectively to week 12 data from stud-</text>
<text top="110" left="55" width="241" height="9" font="font5" id="p1_t10" reading_order_no="7" segment_no="4" tag_type="text">ies that were completed after derivation of the endpoint.</text>
<text top="122" left="55" width="241" height="9" font="font5" id="p1_t11" reading_order_no="8" segment_no="4" tag_type="text">For this paper data analyses were performed on the ITT</text>
<text top="134" left="55" width="241" height="9" font="font5" id="p1_t12" reading_order_no="9" segment_no="4" tag_type="text">subject populations enrolled in an international rand-</text>
<text top="145" left="55" width="241" height="9" font="font5" id="p1_t13" reading_order_no="10" segment_no="4" tag_type="text">omized, double-blind, placebo-controlled, parallel-</text>
<text top="157" left="55" width="241" height="9" font="font5" id="p1_t14" reading_order_no="11" segment_no="4" tag_type="text">group, multicentre trial (IMP 24011, ClinicalTrial.gov reg-</text>
<text top="169" left="55" width="241" height="9" font="font5" id="p1_t15" reading_order_no="12" segment_no="4" tag_type="text">istration number NCT00256139) consisting of an initial</text>
<text top="181" left="55" width="241" height="9" font="font5" id="p1_t16" reading_order_no="13" segment_no="4" tag_type="text">12-week, double-blind treatment period. PASI 75</text>
<text top="192" left="55" width="241" height="9" font="font5" id="p1_t17" reading_order_no="14" segment_no="4" tag_type="text">responders entered an observation period until relapse or</text>
<text top="204" left="55" width="241" height="9" font="font5" id="p1_t18" reading_order_no="15" segment_no="4" tag_type="text">up to 24 weeks, after which patients received 12 weeks of</text>
<text top="216" left="55" width="241" height="9" font="font5" id="p1_t19" reading_order_no="16" segment_no="4" tag_type="text">open-label re-treatment. Non-responders went directly to</text>
<text top="228" left="55" width="241" height="9" font="font5" id="p1_t20" reading_order_no="17" segment_no="4" tag_type="text">an extended treatment period of 12 weeks. The primary</text>
<text top="239" left="55" width="241" height="9" font="font5" id="p1_t21" reading_order_no="18" segment_no="4" tag_type="text">objective of the study was to evaluate the safety and effi-</text>
<text top="251" left="55" width="121" height="9" font="font5" id="p1_t22" reading_order_no="19" segment_no="4" tag_type="text">cacy of efalizumab 1.0 mg kg</text>
<text top="251" left="176" width="8" height="6" font="font6" id="p1_t23" reading_order_no="20" segment_no="4" tag_type="text">-1 </text>
<text top="251" left="184" width="112" height="9" font="font5" id="p1_t24" reading_order_no="21" segment_no="4" tag_type="text">given subcutaneously once</text>
<text top="263" left="55" width="241" height="9" font="font5" id="p1_t25" reading_order_no="22" segment_no="4" tag_type="text">weekly for 12 weeks compared with placebo in moderate-</text>
<text top="275" left="55" width="241" height="9" font="font5" id="p1_t26" reading_order_no="23" segment_no="4" tag_type="text">to-severe patients, and in a cohort of "high-need" patients</text>
<text top="286" left="55" width="241" height="9" font="font5" id="p1_t27" reading_order_no="24" segment_no="4" tag_type="text">for whom existing therapies were inadequate or unsuita-</text>
<text top="298" left="55" width="241" height="9" font="font5" id="p1_t28" reading_order_no="25" segment_no="4" tag_type="text">ble. An initial cohort of moderate-to-severe patients was</text>
<text top="310" left="55" width="241" height="9" font="font5" id="p1_t29" reading_order_no="26" segment_no="4" tag_type="text">recruited, on whom an interim analysis was performed</text>
<text top="322" left="55" width="241" height="9" font="font5" id="p1_t30" reading_order_no="27" segment_no="4" tag_type="text">showing efalizumab efficacy versus placebo. After this,</text>
<text top="333" left="55" width="164" height="9" font="font5" id="p1_t31" reading_order_no="28" segment_no="4" tag_type="text">only high-need patients were recruited.</text>
<text top="357" left="55" width="241" height="9" font="font5" id="p1_t32" reading_order_no="29" segment_no="10" tag_type="text">High-need patients were defined as those patients who</text>
<text top="369" left="55" width="241" height="9" font="font5" id="p1_t33" reading_order_no="30" segment_no="10" tag_type="text">had failed treatment on, were intolerant of, or had con-</text>
<text top="380" left="55" width="241" height="9" font="font5" id="p1_t34" reading_order_no="31" segment_no="10" tag_type="text">traindications to at least two currently available systemic</text>
<text top="392" left="55" width="241" height="9" font="font5" id="p1_t35" reading_order_no="32" segment_no="10" tag_type="text">therapies (e.g., photochemotherapy, cyclosporin, corti-</text>
<text top="404" left="55" width="241" height="9" font="font5" id="p1_t36" reading_order_no="33" segment_no="10" tag_type="text">costeroids, methotrexate, oral retinoids, mycophenolate</text>
<text top="416" left="55" width="241" height="9" font="font5" id="p1_t37" reading_order_no="34" segment_no="10" tag_type="text">mofetil, thioguanine, hydroxyurea, sirolimus, azathio-</text>
<text top="427" left="55" width="110" height="9" font="font5" id="p1_t38" reading_order_no="35" segment_no="10" tag_type="text">prine, 6-mercaptopurine).</text>
<text top="451" left="55" width="241" height="9" font="font5" id="p1_t39" reading_order_no="36" segment_no="14" tag_type="text">SPC was analyzed for the first 12-week treatment period</text>
<text top="463" left="55" width="119" height="9" font="font5" id="p1_t40" reading_order_no="37" segment_no="14" tag_type="text">for which data are available.</text>
<text top="486" left="55" width="34" height="9" font="font4" id="p1_t41" reading_order_no="38" segment_no="15" tag_type="title"><i><b>Patients</b></i></text>
<text top="498" left="55" width="241" height="9" font="font5" id="p1_t42" reading_order_no="39" segment_no="16" tag_type="text">Inclusion and exclusion criteria were similar for all studies</text>
<text top="510" left="55" width="241" height="9" font="font5" id="p1_t43" reading_order_no="40" segment_no="16" tag_type="text">included in the analysis, except for the high-need cohort,</text>
<text top="521" left="55" width="241" height="9" font="font5" id="p1_t44" reading_order_no="41" segment_no="16" tag_type="text">as already explained. Patients were required either to have</text>
<text top="533" left="55" width="241" height="9" font="font5" id="p1_t45" reading_order_no="42" segment_no="16" tag_type="text">received previous systemic treatment for psoriasis or to be</text>
<text top="545" left="55" width="241" height="9" font="font5" id="p1_t46" reading_order_no="43" segment_no="16" tag_type="text">a candidate for such treatment without prior history. All</text>
<text top="557" left="55" width="241" height="9" font="font5" id="p1_t47" reading_order_no="44" segment_no="16" tag_type="text">patients enrolled were 18 to 75 years old with at least a 6-</text>
<text top="568" left="55" width="241" height="9" font="font5" id="p1_t48" reading_order_no="45" segment_no="16" tag_type="text">month history of moderate-to-severe plaque psoriasis</text>
<text top="87" left="313" width="38" height="9" font="font5" id="p1_t49" reading_order_no="46" segment_no="2" tag_type="text">covering </text>
<text top="84" left="353" width="5" height="13" font="font7" id="p1_t50" reading_order_no="47" segment_no="2" tag_type="text">â‰¥</text>
<text top="87" left="358" width="196" height="9" font="font5" id="p1_t51" reading_order_no="48" segment_no="2" tag_type="text">10% of total body surface area (BSA), with a</text>
<text top="98" left="313" width="153" height="9" font="font5" id="p1_t52" reading_order_no="49" segment_no="2" tag_type="text">minimum PASI of 12.0 at screening.</text>
<text top="122" left="313" width="241" height="9" font="font5" id="p1_t53" reading_order_no="50" segment_no="5" tag_type="text">The total number of all patients for the prospective analy-</text>
<text top="134" left="313" width="241" height="9" font="font5" id="p1_t54" reading_order_no="51" segment_no="5" tag_type="text">sis using study IMP 24011 was 793, of whom 526 were</text>
<text top="145" left="313" width="81" height="9" font="font5" id="p1_t55" reading_order_no="52" segment_no="5" tag_type="text">high-need patients.</text>
<text top="169" left="313" width="44" height="9" font="font4" id="p1_t56" reading_order_no="53" segment_no="6" tag_type="title"><i><b>Treatment</b></i></text>
<text top="181" left="313" width="241" height="9" font="font5" id="p1_t57" reading_order_no="54" segment_no="7" tag_type="text">Study treatment efalizumab 1 mg/kg/week was adminis-</text>
<text top="192" left="313" width="241" height="9" font="font5" id="p1_t58" reading_order_no="55" segment_no="7" tag_type="text">tered via subcutaneous injection once weekly for 12</text>
<text top="204" left="313" width="241" height="9" font="font5" id="p1_t59" reading_order_no="56" segment_no="7" tag_type="text">weeks. The first weekly dose of efalizumab was given at a</text>
<text top="216" left="313" width="140" height="9" font="font5" id="p1_t60" reading_order_no="57" segment_no="7" tag_type="text">conditioning dose of 0.7 mg kg</text>
<text top="215" left="453" width="6" height="6" font="font6" id="p1_t61" reading_order_no="58" segment_no="7" tag_type="text">-1</text>
<text top="216" left="459" width="95" height="9" font="font5" id="p1_t62" reading_order_no="59" segment_no="7" tag_type="text">, followed by the full</text>
<text top="228" left="313" width="95" height="9" font="font5" id="p1_t63" reading_order_no="60" segment_no="7" tag_type="text">dose level of 1.0 mg kg</text>
<text top="227" left="408" width="6" height="6" font="font6" id="p1_t64" reading_order_no="61" segment_no="7" tag_type="text">-1</text>
<text top="228" left="414" width="140" height="9" font="font5" id="p1_t65" reading_order_no="62" segment_no="7" tag_type="text">. No other systemic psoriasis ther-</text>
<text top="239" left="313" width="209" height="9" font="font5" id="p1_t66" reading_order_no="63" segment_no="7" tag_type="text">apy or phototherapy was allowed during the trial.</text>
<text top="263" left="313" width="106" height="9" font="font4" id="p1_t67" reading_order_no="64" segment_no="8" tag_type="title"><i><b>Assessment of benefit:risk</b></i></text>
<text top="275" left="313" width="241" height="9" font="font5" id="p1_t68" reading_order_no="65" segment_no="9" tag_type="text">Conventional physician-assessed endpoint data such as</text>
<text top="286" left="313" width="241" height="9" font="font5" id="p1_t69" reading_order_no="66" segment_no="9" tag_type="text">PASI, and patient outcome measures such as DLQI, were</text>
<text top="298" left="313" width="241" height="9" font="font5" id="p1_t70" reading_order_no="67" segment_no="9" tag_type="text">collected for the 12-week timepoint. Safety was assessed</text>
<text top="310" left="313" width="241" height="9" font="font5" id="p1_t71" reading_order_no="68" segment_no="9" tag_type="text">in terms of the incidence, severity, and relationship to</text>
<text top="322" left="313" width="241" height="9" font="font5" id="p1_t72" reading_order_no="69" segment_no="9" tag_type="text">treatment of adverse events (including serious adverse</text>
<text top="333" left="313" width="241" height="9" font="font5" id="p1_t73" reading_order_no="70" segment_no="9" tag_type="text">events) and the incidence of treatment-emergent labora-</text>
<text top="345" left="313" width="241" height="9" font="font5" id="p1_t74" reading_order_no="71" segment_no="9" tag_type="text">tory abnormalities. SPC for efalizumab was calculated</text>
<text top="357" left="313" width="106" height="9" font="font5" id="p1_t75" reading_order_no="72" segment_no="9" tag_type="text">from these 12-week data.</text>
<text top="381" left="313" width="36" height="10" font="font8" id="p1_t76" reading_order_no="73" segment_no="11" tag_type="title"><b>Results</b></text>
<text top="392" left="313" width="111" height="9" font="font4" id="p1_t77" reading_order_no="74" segment_no="12" tag_type="title"><i><b>Retrospective SPC analysis</b></i></text>
<text top="404" left="313" width="241" height="9" font="font5" id="p1_t78" reading_order_no="75" segment_no="13" tag_type="text"><a href="">Table 2 shows the SPC outco</a>me data from the retrospec-</text>
<text top="416" left="313" width="241" height="9" font="font5" id="p1_t79" reading_order_no="76" segment_no="13" tag_type="text">tive analyses. The results were similar between the studies.</text>
<text top="427" left="313" width="241" height="9" font="font5" id="p1_t80" reading_order_no="77" segment_no="13" tag_type="text">At 12 weeks, SPC was achieved by 46.3%, 37.1%, and</text>
<text top="439" left="313" width="241" height="9" font="font5" id="p1_t81" reading_order_no="78" segment_no="13" tag_type="text">37.9% of efalizumab-treated patients for studies ACD</text>
<text top="451" left="313" width="241" height="9" font="font5" id="p1_t82" reading_order_no="79" segment_no="13" tag_type="text">2058, ACD 2059, and ACD 2390, respectively. When</text>
<text top="463" left="313" width="241" height="9" font="font5" id="p1_t83" reading_order_no="80" segment_no="13" tag_type="text">pooled, 39.4% of patients achieved SPC at week 12, com-</text>
<text top="474" left="313" width="128" height="9" font="font5" id="p1_t84" reading_order_no="81" segment_no="13" tag_type="text">pared with 10.4% for placebo.</text>
<text top="498" left="313" width="185" height="9" font="font4" id="p1_t85" reading_order_no="82" segment_no="17" tag_type="title"><i><b>Prospective SPC analysis in study IMP 24011</b></i></text>
<text top="510" left="313" width="241" height="9" font="font5" id="p1_t86" reading_order_no="83" segment_no="18" tag_type="text">In the study IMP 24011, DLQI was administrated to 494</text>
<text top="521" left="313" width="241" height="9" font="font5" id="p1_t87" reading_order_no="84" segment_no="18" tag_type="text">of the 793 patients (165 randomized to placebo and 329</text>
<text top="533" left="313" width="241" height="9" font="font5" id="p1_t88" reading_order_no="85" segment_no="18" tag_type="text">to efalizumab 1.0 mg/kg/wk), as appropriately validated</text>
<text top="545" left="313" width="241" height="9" font="font5" id="p1_t89" reading_order_no="86" segment_no="18" tag_type="text">translations of the questionnaire were not available for</text>
<text top="557" left="313" width="241" height="9" font="font5" id="p1_t90" reading_order_no="87" segment_no="18" tag_type="text">use in Greece, Israel, Portugal or Russia. Thus, determina-</text>
<text top="568" left="313" width="241" height="9" font="font5" id="p1_t91" reading_order_no="88" segment_no="18" tag_type="text">tion of the percentages of patients achieving SPC at week</text>
<text top="592" left="55" width="250" height="7" font="font9" id="p1_t92" reading_order_no="89" segment_no="19" tag_type="title"><b>Table 2: Retrospective SPC results (Good control level) at week 12</b></text>
<text top="610" left="95" width="18" height="7" font="font10" id="p1_t93" reading_order_no="90" segment_no="20" tag_type="table">Study</text>
<text top="610" left="231" width="60" height="7" font="font10" id="p1_t94" reading_order_no="91" segment_no="20" tag_type="table">Treatment Group</text>
<text top="610" left="412" width="98" height="7" font="font10" id="p1_t95" reading_order_no="92" segment_no="20" tag_type="table">Safe Psoriasis Control (SPC)*</text>
<text top="632" left="81" width="48" height="7" font="font10" id="p1_t96" reading_order_no="93" segment_no="20" tag_type="table">ACD2058[14]</text>
<text top="632" left="158" width="59" height="7" font="font10" id="p1_t97" reading_order_no="94" segment_no="20" tag_type="table">Placebo (n = 170)</text>
<text top="632" left="442" width="38" height="7" font="font10" id="p1_t98" reading_order_no="95" segment_no="20" tag_type="table">18 (10.6 %)</text>
<text top="642" left="158" width="115" height="7" font="font10" id="p1_t99" reading_order_no="96" segment_no="20" tag_type="table">Efalizumab 1.0 mg/kg/wk (n = 162)</text>
<text top="642" left="442" width="38" height="7" font="font10" id="p1_t100" reading_order_no="97" segment_no="20" tag_type="table">75 (46.3 %)</text>
<text top="653" left="81" width="48" height="7" font="font10" id="p1_t101" reading_order_no="98" segment_no="20" tag_type="table">ACD2059[13]</text>
<text top="653" left="158" width="59" height="7" font="font10" id="p1_t102" reading_order_no="99" segment_no="20" tag_type="table">Placebo (n = 122)</text>
<text top="653" left="444" width="34" height="7" font="font10" id="p1_t103" reading_order_no="100" segment_no="20" tag_type="table">12 (9.8 %)</text>
<text top="663" left="158" width="115" height="7" font="font10" id="p1_t104" reading_order_no="101" segment_no="20" tag_type="table">Efalizumab 1.0 mg/kg/wk (n = 232)</text>
<text top="663" left="442" width="38" height="7" font="font10" id="p1_t105" reading_order_no="102" segment_no="20" tag_type="table">86 (37.1 %)</text>
<text top="673" left="81" width="48" height="7" font="font10" id="p1_t106" reading_order_no="103" segment_no="20" tag_type="table">ACD2390[12]</text>
<text top="673" left="158" width="59" height="7" font="font10" id="p1_t107" reading_order_no="104" segment_no="20" tag_type="table">Placebo (n = 187)</text>
<text top="673" left="442" width="38" height="7" font="font10" id="p1_t108" reading_order_no="105" segment_no="20" tag_type="table">20 (10.7 %)</text>
<text top="683" left="158" width="115" height="7" font="font10" id="p1_t109" reading_order_no="106" segment_no="20" tag_type="table">Efalizumab 1.0 mg/kg/wk (n = 369)</text>
<text top="683" left="440" width="42" height="7" font="font10" id="p1_t110" reading_order_no="107" segment_no="20" tag_type="table">140 (37.9 %)</text>
<text top="694" left="80" width="49" height="7" font="font10" id="p1_t111" reading_order_no="108" segment_no="20" tag_type="table">Pooled studies</text>
<text top="694" left="158" width="59" height="7" font="font10" id="p1_t112" reading_order_no="109" segment_no="20" tag_type="table">Placebo (n = 479)</text>
<text top="694" left="443" width="36" height="7" font="font10" id="p1_t113" reading_order_no="110" segment_no="20" tag_type="table">50 (10.4%)</text>
<text top="704" left="158" width="115" height="7" font="font10" id="p1_t114" reading_order_no="111" segment_no="20" tag_type="table">Efalizumab 1.0 mg/kg/wk (n = 763)</text>
<text top="704" left="441" width="40" height="7" font="font10" id="p1_t115" reading_order_no="112" segment_no="20" tag_type="table">301 (39.4%)</text>
<text top="726" left="59" width="408" height="7" font="font10" id="p1_t116" reading_order_no="113" segment_no="21" tag_type="text">* SPC is defined by PASI &lt;= 8 and DLQI &lt;= 6 and No SAEs and No Severe AEs related to Study Drug and not withdrawn</text>
</page>
</pdf2xml>
